Frontiers in endocrinology

Short-term oleoylethanolamide (TRPTI™) supplements increase gut hormone responses

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Oleoylethanolamide (OEA) is involved in nutrient sensing and gut-derived hormonal signaling.

  • TRPTI™ is a formulation of OEA aimed at supporting metabolism and appetite regulation.
  • The study assessed the immediate metabolic effects of TRPTI™ in healthy adults.
  • Controlled feeding conditions were utilized to evaluate the acute effects of TRPTI™.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Author PV is an employee of the study sponsor Gencor Pacific. The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
PubMed

Related papers

Aug '06
Single doses of sitagliptin's effects on hormone and blood sugar levels after glucose intake in type 2 diabetes
cited by 423 papers
randomized controlled trial
Apr '16
Blood Levels of Hormones That Help Control Blood Sugar and Their Breakdown in People with Sleep Apnea
top 10% journal
cited by 29 papers
research support, non-u.s. gov't
Feb '17
Dipeptidyl peptidase-4 inhibitor treatment raises active GIP levels more than active GLP-1 in non-diabetic people
top 5% journal
cited by 35 papers
research support, non-u.s. gov't
Feb '02
Blocking an enzyme that breaks down active incretin hormones lowers meal-triggered incretin release in dogs
top 20% journal
cited by 123 papers
research support, non-u.s. gov't

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief